MA46563B1 - Compositions dispersibles - Google Patents

Compositions dispersibles

Info

Publication number
MA46563B1
MA46563B1 MA46563A MA46563A MA46563B1 MA 46563 B1 MA46563 B1 MA 46563B1 MA 46563 A MA46563 A MA 46563A MA 46563 A MA46563 A MA 46563A MA 46563 B1 MA46563 B1 MA 46563B1
Authority
MA
Morocco
Prior art keywords
compositions
dispersible compositions
useful
dispersible
rilpivirine
Prior art date
Application number
MA46563A
Other languages
English (en)
Other versions
MA46563A (fr
Inventor
Harshad Patankar
Nicolaas Martha Felix Goyvaerts
Rajan Gopal Rajan Ranga
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA46563A publication Critical patent/MA46563A/fr
Publication of MA46563B1 publication Critical patent/MA46563B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Furan Compounds (AREA)

Abstract

La présente invention concerne des compositions dispersibles comprenant de la rilpivirine ou un sel d'addition d'acide pharmaceutiquement acceptable de celle-ci en tant que principe actif. Ces compositions s'avèrent utiles dans le traitement d'une infection par le vih et leurs propriétés de dispersibilité les rend utiles en particulier auprès de la population pédiatrique ou gériatrique.
MA46563A 2016-10-24 2017-10-23 Compositions dispersibles MA46563B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (fr) 2016-10-24 2017-10-23 Compositions dispersibles

Publications (2)

Publication Number Publication Date
MA46563A MA46563A (fr) 2019-08-28
MA46563B1 true MA46563B1 (fr) 2024-01-31

Family

ID=60262899

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46563A MA46563B1 (fr) 2016-10-24 2017-10-23 Compositions dispersibles

Country Status (21)

Country Link
US (2) US11065198B2 (fr)
EP (2) EP3528791B1 (fr)
JP (2) JP7197474B2 (fr)
KR (2) KR20190073450A (fr)
CN (1) CN110191704A (fr)
CA (1) CA3039562A1 (fr)
DK (1) DK3528791T3 (fr)
ES (1) ES2970870T3 (fr)
FI (1) FI3528791T3 (fr)
HR (1) HRP20240118T1 (fr)
HU (1) HUE064823T2 (fr)
LT (1) LT3528791T (fr)
MA (1) MA46563B1 (fr)
MX (1) MX2019004767A (fr)
PL (1) PL3528791T3 (fr)
PT (1) PT3528791T (fr)
RS (1) RS65159B1 (fr)
SI (1) SI3528791T1 (fr)
SM (1) SMT202400060T1 (fr)
TW (1) TWI821163B (fr)
WO (1) WO2018077815A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021026916A2 (pt) * 2019-07-03 2022-05-10 Janssen Sciences Ireland Unlimited Co Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer
WO2021253380A1 (fr) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Formulations orales et leurs utilisations
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (fr) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Comprimés dispersibles enrobés par compression
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CN102702111B (zh) 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
WO2006024668A1 (fr) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
DK1632232T6 (da) 2004-09-02 2022-04-19 Janssen Pharmaceutica Nv Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
UA92467C2 (ru) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
PT2040671T (pt) 2006-06-23 2018-03-14 Janssen Sciences Ireland Uc Suspensões aquosas de tmc278
US20160346198A1 (en) * 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015136294A1 (fr) 2014-03-13 2015-09-17 Cipla Limited Composition pharmaceutique comprenant de la rilpivirine
RU2740903C2 (ru) * 2014-05-16 2021-01-21 Вивус, Инк. Пероральная рассыпающаяся лекарственная форма для введения аванафила и связанные с ней способы получения и применения

Also Published As

Publication number Publication date
CN110191704A (zh) 2019-08-30
MA46563A (fr) 2019-08-28
CA3039562A1 (fr) 2018-05-03
TW201828927A (zh) 2018-08-16
MX2019004767A (es) 2019-07-01
WO2018077815A1 (fr) 2018-05-03
EP4248947A3 (fr) 2023-11-22
HRP20240118T1 (hr) 2024-04-12
ES2970870T3 (es) 2024-05-31
EP3528791A1 (fr) 2019-08-28
EP4248947A2 (fr) 2023-09-27
JP2020500168A (ja) 2020-01-09
RU2019115672A (ru) 2020-11-24
KR20190073450A (ko) 2019-06-26
HUE064823T2 (hu) 2024-04-28
JP2023011659A (ja) 2023-01-24
RU2019115672A3 (fr) 2021-01-21
LT3528791T (lt) 2024-05-27
KR102861006B1 (ko) 2025-09-16
SI3528791T1 (sl) 2024-04-30
US11065198B2 (en) 2021-07-20
BR112019007564A2 (pt) 2019-07-02
PT3528791T (pt) 2024-02-19
DK3528791T3 (da) 2024-01-29
US20220008333A1 (en) 2022-01-13
JP7197474B2 (ja) 2022-12-27
US20200069579A1 (en) 2020-03-05
KR20240011873A (ko) 2024-01-26
FI3528791T3 (fi) 2024-01-30
TWI821163B (zh) 2023-11-11
PL3528791T3 (pl) 2024-04-02
EP3528791B1 (fr) 2023-12-06
RS65159B1 (sr) 2024-02-29
SMT202400060T1 (it) 2024-03-13

Similar Documents

Publication Publication Date Title
MA41411B1 (fr) Compositions dispersibles
MA51530B1 (fr) Composés cycliques fondus
JOP20190193B1 (ar) ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
MX388757B (es) Profármacos de éster alifático antivíricos de tenofovir.
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA34002B1 (fr) Thérapie antivirale
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA46038A (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MY186986A (en) Compositions and methods of use of phorbol esters
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
MA43960A (fr) Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1
MX2019004767A (es) Composiciones dispersables.
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA44384A (fr) Formulation d'amidon de pois d'acide polyinosinique-polycytidylique (poly(i:c)) pour la prévention et/ou le traitement d'infections des voies respiratoires supérieures
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
MA45609B1 (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite